$4bn deal strengthens Danaher’s life sciences portfolio

Instrumentation conglomerate Danaher has agreed to buy medical diagnostics specialist Cepheid for around $4 billion (£3 billion).

The move will add Cepheid’s molecular diagnostics technology, including its GeneXpert testing systems for a range of diseases, to Danaher’s life sciences portfolio. Danaher intends to apply its ‘Danaher Business System’ to improve operational efficiency, enhance profit margins and drive growth for Cepheid’s products.

Topics